about
Regular physical exercise training assists in preventing type 2 diabetes development: focus on its antioxidant and anti-inflammatory properties.Diabetic nephropathy amelioration by a low-dose sitagliptin in an animal model of type 2 diabetes (Zucker diabetic fatty rat).Markers of increased cardiovascular risk in postmenopausal women: focus on oxidized-LDL and HDL subpopulations.New markers of early cardiovascular risk in multiple sclerosis patients: oxidized-LDL correlates with clinical staging.Implication of low HDL-c levels in patients with average LDL-c levels: a focus on oxidized LDL, large HDL subpopulation, and adiponectin.Sitagliptin prevents aggravation of endocrine and exocrine pancreatic damage in the Zucker Diabetic Fatty rat - focus on amelioration of metabolic profile and tissue cytoprotective propertiesSitagliptin prevents inflammation and apoptotic cell death in the kidney of type 2 diabetic animalsThe Place of Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Therapeutics: A "Me Too" or "the Special One" Antidiabetic Class?Serum and renal tissue markers of nephropathy in rats under immunosuppressive therapy: cyclosporine versus sirolimus.Renoprotective Effects of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin: A Review in Type 2 Diabetes.Recombinant human erythropoietin treatment protects the cardio-renal axis in a model of moderate chronic renal failure.Emergent biomarkers of residual cardiovascular risk in patients with low HDL-c and/or high triglycerides and average LDL-c concentrations: focus on HDL subpopulations, Oxidized LDL, adiponectin, and uric acid.Effect of Recombinant Human Erythropoietin in a Rat Model of Moderate Chronic Renal Failure - Focus on Inflammation, Oxidative Stress and Function/RenoprotectionProtective effects of the dipeptidyl peptidase IV inhibitor sitagliptin in the blood-retinal barrier in a type 2 diabetes animal model
P50
Q30399061-A944A7D9-5B92-4B3A-A5A9-B769DB373418Q35607330-27A58742-859F-47E2-9EB4-18F5B8A98B2FQ37176675-D3720185-5C95-4BB9-B58A-C94D91B4915AQ37259105-AD5F1F5F-6AF7-43C7-B5BF-A71C94F45CA1Q37298694-4C265624-73F7-43B3-9407-F044A0B721CDQ37720797-DAF2AB6C-32D7-49AE-80F9-39F1EDE741A0Q37725539-C314A36C-60EA-4F57-9CF1-3FB45B593CB7Q38527885-FF5878A2-6374-47CE-87B3-3A06FAB01D1FQ40249744-FAB6D44E-7FC8-496C-8527-FB8ECE44AA06Q42876331-AD008D78-6532-4B92-87AC-2CA0CA3407C8Q45982051-56CF29C0-E088-4DA3-BA1C-E31652B2A564Q55710149-D80DF247-5F78-4A44-86BF-F20F009F4CA8Q60176037-6FF10027-8C4F-4045-9FDA-3B012B0BC82EQ61952011-DDDA64F8-5434-4F16-891D-F7D92D388735
P50
description
forsker
@nb
researcher ORCID 0000-0002-6346-8319
@en
wetenschapper
@nl
name
E. Teixeira-Lemos
@ast
E. Teixeira-Lemos
@nl
Edite Teixeira-Lemos
@en
Edite Teixeira-Lemos
@es
Edite Teixeira-Lemos
@nb
type
label
E. Teixeira-Lemos
@ast
E. Teixeira-Lemos
@nl
Edite Teixeira-Lemos
@en
Edite Teixeira-Lemos
@es
Edite Teixeira-Lemos
@nb
altLabel
E. Teixeira-Lemos
@en
prefLabel
E. Teixeira-Lemos
@ast
E. Teixeira-Lemos
@nl
Edite Teixeira-Lemos
@en
Edite Teixeira-Lemos
@es
Edite Teixeira-Lemos
@nb
P106
P1153
22836614300
P31
P496
0000-0002-6346-8319